NIH Awards Grant to TTUHSC Researcher
Project To Investigate New Therapy Targets for Rare Cancer
Pulmonary lymphangioleiomyomatosis (LAM) is a rare form of cancer that affects up to eight of every one million women of reproductive age worldwide. This disease is characterized by the uncontrolled growth (proliferation) of tumor cells that are biologically similar to smooth muscle cells in the lungs, kidneys and lymphatics; these cells will spread and invade various locations throughout the body. Currently there are approximately 1,500 confirmed cases in the U.S.
The most common symptom associated with LAM is shortness of breath, especially upon exertion. In most cases, the disease progresses slowly and over time can lead to lung collapses and ultimately respiratory failure.
To better understand the role of extracellular vesicles (EV) in the spread and progression of LAM, the National Institutes of Health (NIH) recently awarded a four-year, $2.8 million grant to Magdalena Karbowniczek, M.D., Ph.D., a professor of immunotherapeutics and biotechnology at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy. Based upon the study’s progress and the availability of funds, the NIH could extend the grant to five years and approximately $3.5 million.
EVs are tiny nanometer size particles released by healthy cells to “communicate” with other cells. Karbowniczek said they also are thought to facilitate cancer metastasis; however, their role in LAM has not yet been explored.
“We hope to establish EVs — and the mechanisms that control their release from [some] cells and uptake by other cells — as targets for new LAM therapy,” Karbowniczek said. “There are currently medications that target EVs that are tested in clinical trials for other cancers; therefore, if we discover that EVs are promoting LAM progression and spread, they can be repurposed for LAM.”
There are two main types of LAM: sporadic LAM, which develops spontaneously, and LAM associated with tuberous sclerosis complex, an inheritable genetic condition manifesting with multiple tumors in different organs. The therapeutic options for LAM patients are very limited, as the only drug currently available for LAM is everolimus, an analog of rapamycin that in some patients can slow the progress of disease. However, everolimus does not stop lung destruction, and the disease relapses once treatment ends.
“We hope that through studies funded by this grant we will be able to identify new therapeutic targets, and that knowledge gained through this work will be instrumental for the development of new therapies for LAM patients,” Karbowniczek added.
The project is a collaboration with the University of Cincinnati (UC); Jane Yu, Ph.D., a professor of internal medicine at the UC College of Medicine also is a co-principal investigator (PI) on this grant. Karbowniczek and Yu have collaborated for almost 20 years after initially investigating LAM together as postdoctoral trainees under Lisa Henske, M.D., a world-renowned LAM expert at Fox Chase Cancer Center in Philadelphia.
TTUHSC co-investigators for the grant include Irene La-Beck, Pharm.D., and Maciej Markiewski, M.D., Ph.D. UC co-investigator Frank X. McCormack, M.D., who leads international randomized trials for LAM, also will provide expertise necessary for these studies.
“This multi-PI grant unifies [our] expertise in LAM again and formalizes a long-lasting collaboration for the benefit of LAM patients,” Karbowniczek said.
Related Stories
National Academy of Inventors Ranks Texas Tech University System Among Top 100 in Patents for Second Consecutive Year
The TTU System, including the TTUHSC and TTUHSC El Paso, ranked 74th on the NAI list of Top 100 U.S. Universities Granted Utility Patents for 2023.
Twelve Full-Time TTUHSC Researchers Named to Latest World’s Top 2% of Scientists Rankings
Last fall, Stanford University/Elsevier’s sixth edition of the World’s Top 2% of Scientists List was released and included 12 full-time and three part-time researchers from TTUHSC.
TTUHSC, TTU Scientists Meet at First Amarillo Research Symposium
In April, the TTUHSC Amarillo campus hosted the inaugural Amarillo Research Symposium.
Recent Stories
PAs and Telehealth: Increasing Access to Patient Care
The PA profession and telehealth were both created to improve and expand access to patient care. PA Abby Buterbaugh discussed the value that her profession and telehealth has brought to health care.
Food Allergy Awareness, Prevention Ahead of Summer Fun
James Tarbox, M.D., Texas Tech Physicians allergist, discussed food allergies and treatments.
National Academy of Inventors Ranks Texas Tech University System Among Top 100 in Patents for Second Consecutive Year
The TTU System, including the TTUHSC and TTUHSC El Paso, ranked 74th on the NAI list of Top 100 U.S. Universities Granted Utility Patents for 2023.